Guardion Health Sciences Inc (GHSI)

$9.1

-0.17

(-1.79%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Guardion Health Sciences Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.93M → 2.99M (in $), with an average increase of 2.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 424.72K → -4.74M (in $), with an average decrease of 1217.6% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 50.3% return, outperforming this stock by 16.6%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 46.5% return, outperforming this stock by 134.9%

Performance

  • $9.03
    $9.35
    $9.10
    downward going graph

    0.75%

    Downside

    Day's Volatility :3.4%

    Upside

    2.67%

    downward going graph
  • $5.01
    $10.75
    $9.10
    downward going graph

    44.95%

    Downside

    52 Weeks Volatility :53.4%

    Upside

    15.35%

    downward going graph

Returns

PeriodGuardion Health Sciences IncIndex (Russel 2000)
3 Months
10.17%
0.0%
6 Months
52.39%
0.0%
1 Year
33.7%
0.0%
3 Years
-88.2%
-20.1%

Highlights

Market Capitalization
10.1M
Book Value
$6.39
Earnings Per Share (EPS)
0.12
PE Ratio
65.83
Wall Street Target Price
40.0
Profit Margin
1.29%
Operating Margin TTM
-23.58%
Return On Assets TTM
-14.66%
Return On Equity TTM
1.48%
Revenue TTM
12.2M
Revenue Per Share TTM
9.64
Quarterly Revenue Growth YOY
7.7%
Gross Profit TTM
4.5M
EBITDA
-3.9M
Diluted Eps TTM
0.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.4
EPS Estimate Next Year
-1.02
EPS Estimate Current Quarter
-0.88
EPS Estimate Next Quarter
-0.66

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Guardion Health Sciences Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 339.56%

Current $9.10
Target $40.00

Company Financials

FY18Y/Y Change
Revenue
942.2K
↑ 115.42%
Net Income
-7.8M
↑ 46.41%
Net Profit Margin
-824.43%
↑ 388.6%
FY19Y/Y Change
Revenue
902.9K
↓ 4.16%
Net Income
-11.1M
↑ 43.38%
Net Profit Margin
-1.2K%
↓ 408.95%
FY20Y/Y Change
Revenue
1.9M
↑ 109.3%
Net Income
-8.6M
↓ 22.97%
Net Profit Margin
-453.95%
↑ 779.43%
FY21Y/Y Change
Revenue
7.2M
↑ 282.74%
Net Income
-24.7M
↑ 188.44%
Net Profit Margin
-342.11%
↑ 111.84%
FY22Y/Y Change
Revenue
11.0M
↑ 52.77%
Net Income
-30.3M
↑ 22.36%
Net Profit Margin
-274.01%
↑ 68.1%
FY23Y/Y Change
Revenue
12.2M
↑ 10.85%
Net Income
158.0K
↓ 100.52%
Net Profit Margin
1.29%
↑ 275.3%
Q4 FY22Q/Q Change
Revenue
2.7M
↑ 2.36%
Net Income
-8.9M
↑ 435.8%
Net Profit Margin
-326.65%
↓ 264.25%
Q1 FY23Q/Q Change
Revenue
2.7M
↑ 0.0%
Net Income
-24.2M
↑ 172.28%
Net Profit Margin
-889.38%
↓ 562.73%
Q2 FY23Q/Q Change
Revenue
2.8M
↑ 2.33%
Net Income
-1.2M
↓ 95.16%
Net Profit Margin
-42.02%
↑ 847.36%
Q3 FY23Q/Q Change
Revenue
3.3M
↑ 19.62%
Net Income
372.6K
↓ 131.78%
Net Profit Margin
11.17%
↑ 53.19%
Q4 FY23Q/Q Change
Revenue
2.9M
↓ 12.03%
Net Income
424.7K
↑ 13.98%
Net Profit Margin
14.47%
↑ 3.3%
Q1 FY24Q/Q Change
Revenue
3.0M
↑ 2.17%
Net Income
-4.7M
↓ 1217.62%
Net Profit Margin
-158.24%
↓ 172.71%
FY18Y/Y Change
Total Assets
3.7M
↓ 50.05%
Total Liabilities
495.3K
↓ 0.92%
FY19Y/Y Change
Total Assets
12.9M
↑ 249.81%
Total Liabilities
845.0K
↑ 70.59%
FY20Y/Y Change
Total Assets
9.9M
↓ 23.42%
Total Liabilities
1.3M
↑ 59.25%
FY21Y/Y Change
Total Assets
23.5M
↑ 137.92%
Total Liabilities
1.2M
↓ 13.58%
FY22Y/Y Change
Total Assets
21.7M
↓ 7.56%
Total Liabilities
8.5M
↑ 632.52%
FY23Y/Y Change
Total Assets
11.9M
↓ 45.04%
Total Liabilities
3.8M
↓ 55.72%
Q4 FY22Q/Q Change
Total Assets
21.7M
↓ 23.18%
Total Liabilities
8.5M
↑ 391.46%
Q1 FY23Q/Q Change
Total Assets
21.7M
↑ 0.0%
Total Liabilities
8.5M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
13.5M
↓ 37.87%
Total Liabilities
6.2M
↓ 26.83%
Q3 FY23Q/Q Change
Total Assets
12.9M
↓ 4.43%
Total Liabilities
5.2M
↓ 16.96%
Q4 FY23Q/Q Change
Total Assets
11.9M
↓ 7.45%
Total Liabilities
3.8M
↓ 27.12%
Q1 FY24Q/Q Change
Total Assets
10.4M
↓ 12.68%
Total Liabilities
7.0M
↑ 85.38%
FY18Y/Y Change
Operating Cash Flow
-4.2M
↑ 22.63%
Investing Cash Flow
-310.2K
↑ 857.98%
Financing Cash Flow
419.8K
↓ 94.82%
FY19Y/Y Change
Operating Cash Flow
-6.0M
↑ 44.47%
Investing Cash Flow
-171.1K
↓ 44.86%
Financing Cash Flow
16.6M
↑ 3865.21%
FY20Y/Y Change
Operating Cash Flow
-8.0M
↑ 32.9%
Investing Cash Flow
-34.7K
↓ 79.7%
Financing Cash Flow
5.5M
↓ 67.25%
FY21Y/Y Change
Operating Cash Flow
-10.6M
↑ 32.82%
Investing Cash Flow
-31.0M
↑ 89185.12%
Financing Cash Flow
37.2M
↑ 582.9%
FY22Y/Y Change
Operating Cash Flow
-7.4M
↓ 30.04%
Investing Cash Flow
5.0M
↓ 116.09%
Financing Cash Flow
14.3M
↓ 61.68%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.4M
↑ 6.38%
Investing Cash Flow
-1.7K
↓ 100.02%
Financing Cash Flow
4.3M
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.4M
↑ 0.0%
Investing Cash Flow
-1.7K
↑ 0.0%
Financing Cash Flow
4.3M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Guardion Health Sciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Guardion Health Sciences Inc
Guardion Health Sciences Inc
15.82%
52.39%
33.7%
-88.2%
-98.31%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
5.15%
26.64%
50.32%
46.7%
76.15%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
1.91%
2.16%
-0.35%
14.98%
14.98%
Zoetis Inc.
Zoetis Inc.
18.72%
-3.66%
-3.75%
-2.05%
67.86%
Viatris Inc.
Viatris Inc.
-2.58%
16.97%
15.73%
-28.65%
-32.93%
Catalent, Inc.
Catalent, Inc.
-1.94%
38.79%
46.52%
-46.41%
19.01%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Guardion Health Sciences Inc
Guardion Health Sciences Inc
65.83
65.83
NA
-2.4
0.01
-0.15
NA
6.39
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
38.49
38.49
0.44
4.06
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.37
28.37
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
33.54
33.54
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.33
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Guardion Health Sciences Inc
Guardion Health Sciences Inc
Buy
$10.1M
-98.31%
65.83
1.29%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.3B
76.15%
38.49
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.9B
14.98%
28.37
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$79.6B
67.86%
33.54
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-32.93%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.0B
19.01%
211.02
-28.44%

Institutional Holdings

  • Renaissance Technologies Corp

    2.98%

  • Vanguard Group Inc

    1.16%

  • BlackRock Inc

    0.79%

  • Tower Research Capital LLC

    0.09%

  • Morgan Stanley - Brokerage Accounts

    0.05%

  • Citigroup Inc

    0.03%

Company Information

by applying the latest science, technology and research, guardion health sciences (ghs) has positioned itself to address the escalating demand for solutions that promise to improve life-diminishing health problems facing the aging baby boomer generation. guardion health sciences is dedicated to applying a scientific discipline and pharmaceutical approach to the development of safe, standardized and effective condition specific solutions. using the individual and collective knowledge of the members of our science advisory board, we will advise healthcare professionals and the public on the importance of medical foods and nutrition to achieve overall good health. the company’s first medical food, lumega-z, is scientifically formulated to restore and maintain the macular protective pigment. a depleted macular pigment is a known contributor to amd. though lumega-z was created with the amd epidemic in mind, its ingredients are also thought to be beneficial for other types of eye disease (i.

Organization
Guardion Health Sciences Inc
Employees
9
CEO
Mr. Robert Neal Weingarten
Industry
Medical/Nursing Services

Discover More

FAQs